Scarica l'app Stockscreener
3.85
1.03%
-0.04
Dopo l'orario di chiusura:
3.85
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
NervGen Pharma (NGEN) Stock Chart and Price History 2026 - MarketBeat
Top NervGen Pharma (NGEN) Competitors 2026 - MarketBeat
NGEN : NervGen Pharma Corp. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
What is the current Price Target and Forecast for NERVGEN PHARMA (NGEN) - Zacks Investment Research
NERVGEN PHARMA (NGEN) - Zacks Investment Research
Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug - Streetwise Reports
H.C. Wainwright reiterates NervGen stock rating on new CFO hire By Investing.com - Investing.com India
H.C. Wainwright reiterates NervGen stock rating on new CFO hire - Investing.com UK
EDGAR Filing Documents for 0001104659-26-049508 - SEC.gov
NervGen Pharma (NGEN) 10K Form and Latest SEC Filings 2026 - MarketBeat
NervGen Pharma (NGEN) Stock Trends and Sentiment 2026 - MarketBeat
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan - TipRanks
NervGen appoints Keith Vendola as chief financial officer - Investing.com UK
NervGen Pharma (NGEN) Stock Forecast and Price Target 2026 - MarketBeat
NervGen Pharma initiated with a Buy at H.C. Wainwright - TipRanks
NervGen Pharma appoints Keith Vendola as CFO - TipRanks
NGEN Initiated Coverage by HC Wainwright & Co. -- Price Target A - GuruFocus
NervGen appoints Keith Vendola as chief financial officer By Investing.com - Investing.com Australia
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer - The Manila Times
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma Corp. Common stock Stock Forecast Summary - Meyka
NervGen Pharma Corp. (NGEN) - Minichart
NervGen (NGEN) Stock Initiates Position (Near Lows) 2026-04-20Risk Analysis - UBND thành phố Hải Phòng
NervGen (NGEN) Stock: Why Short Sellers Target It (+1.19%) 2026-04-15Institutional Buying - Xã Vĩnh Công
NervGen's SCI Drug Shows 'Durable Improvement' in Chronic Injury - BriefGlance
NervGen Pharma initiated with a Buy at Lucid Capital - TipRanks
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference - Bitget
NervGen Pharma to Participate in the H.C. Wainwright - GlobeNewswire
NGEN Options Volatility — NASDAQ:NGEN - TradingView
NGEN Options Chain — NASDAQ:NGEN - TradingView
Is NervGen Pharma still undervalued? - Cantech Letter
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
NGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - Sahm
NervGen receives FDA alignment on Phase 3 trial for tetraplegia By Investing.com - Investing.com South Africa
NervGen Pharma Says Phase 3 Chronic Tetraplegia Study Design Aligns With US FDA - marketscreener.com
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia - TipRanks
NervGen receives FDA alignment on Phase 3 trial for tetraplegia - Investing.com
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting - TipRanks
NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion. - Bitget
Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study of NVG-291 for chronic tetraplegia - marketscreener.com
Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia - TradingView — Track All Markets
FDA aligns on NervGen trial targeting hand use in tetraplegia - Stock Titan
NervGen Pharma Announces Successful End-of-Phase 2 Meeting - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN) - The Globe and Mail
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times
1.87%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):